Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.37 |
| ▸ | FABP7 | O15540 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 6/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | EYA2 | O00167 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307644 | 0.90 | KMT2A (0.41) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL29883728 | 0.90 | KMT2A (0.41) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL307102 | 0.85 | KMT2A (0.42) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL28416919 | 0.84 | KMT2A (0.40) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL31040664 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 | |
| SCHEMBL17108591 | 0.84 | KMT2A (0.44) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL30861809 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 | |
| SCHEMBL28414420 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 | |
| SCHEMBL21838102 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 | |
| SCHEMBL3792078 | 0.83 | KMT2A (0.54) | KMT2AFABP5FABP7TLR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951963-B2 | Process for preparing N-protected β-amino aldehyde compounds | THERAVANCE, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2003106399-A2 | PROCESS FOR PREPARING N-PROTECTED β-AMINO ALDEHYDE COMPOUNDS | THERAVANCE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030233010-A1 | Process for perparing N-protected beta-amino aldehyde compounds | CUMBERLAND PHARMACEUTICALS INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030233010-A1 | Process for perparing N-protected beta-amino aldehyde compounds | DNPEP, PREP, ANPEP | KMT2A 2254/4885FABP5 2344/4885FABP7 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.